Gilead Sciences

Gilead Sciences: Underestimated Biotech Giant with Surprising Growth Potential

吉利德科学

Gilead Sciences CEO O'Day Buys 115,640 Shares, Sells Same Amount at $150/Shr.

Gilead's Yescarta Wins FDA Label Update, Expands Patient Eligibility

Gilead Sciences's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross.

Novartis

Bristol-Myers Squibb

Sangamo Therapeutics

Agereh Expands Intelligent Transportation Portfolio with Launch of Smart Door Sensor and Retains Hillside C&M Inc.

Catalyst<ul> <li>Most analysts rate GILD Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant in the technical analysis.</li></ul>

Key Factors

Gilead's Q4 revenue is forecast to rise 0.1% to $7.57 billion, with a 3.7% decline in earnings per share.Gilead's CEO O'Day purchased and sold 115,640 shares on February 5 at $66.01 and $150 per share respectively.Gilead's Yescarta received an FDA label update expanding eligibility for a subset of lymphoma patients.Gilead's HIV product sales grew 4% YoY to $5.3 billion in Q4, driven by Biktarvy and Descovy demand.Gilead's liver disease portfolio sales rose 12% YoY to $819 million in Q4.

Recent Updates

GILD News